{"id":739768,"date":"2023-03-14T07:35:12","date_gmt":"2023-03-14T11:35:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/"},"modified":"2023-03-14T07:35:12","modified_gmt":"2023-03-14T11:35:12","slug":"repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/","title":{"rendered":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., March  14, 2023  (GLOBE NEWSWIRE) &#8212; Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.\u00a0 Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT.<\/p>\n<p>A live webcast of the presentation will be accessible through the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VOKzRS9bE_rtvSw28td9VYRpBrhBOQhl9H0sTCdQiJ9pRwLbxLWYeOlEYLq3QzL60vyKoL3-qpXj9R4kM-K5MsjVCGYCrGesS5lJ7S8DbBzwtgCx3ea7gNxeowCKpK6M9a2NS-hroalBjm7T2tVTMb_CvIbkQRwMqEftVRgJcYHbmH6TkMgfv0KAQPqymZQLr2ZkJqAQetj66WXxFgSJvqGq9mAvgMWY5w04iGP8Ck0WztgE5lWUG4EuIFtH9AH4G83-br9MP4vh37JNSdmD3Tbuifn32jxVeTNTBICEcNu9yzH3CSMpxgssNhXxklFD\" rel=\"nofollow noopener\" target=\"_blank\">Investor Relations<\/a>\u00a0section of the Company\u2019s website, and will be available for replay for a limited period of time following the conference event.<\/p>\n<p>\n        <strong>About Repligen Corporation<\/strong><br \/>\n        <br \/>Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5-NkMu6kXhanddSrE0Zyyt12JjicHpUKrdQ8sY9vdBH7FFjLFQ1DDLfGn6l9qWvkPGNhrG51MPCoY3ozepKB1KsIaWl0HObPIcEQHeL18l4=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.repligen.com<\/a>. Follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V-Vmk0PB1HR9ywp3QiJ8nGVPSfWsgdQTJgzHupkKAdcL35aNR7ICBOHDt6ScP8JkAUEmAP-JllxuZSW_alNac8H8DIn-WrWTtkF4cz9NPo_ALFTHJ-w3_VUtwplJJBqu\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O4pgtKp2mHRheCmVpWhQYq4_xutFPKzslT1xK1RqBcg77wW0nhZ9k1UgJE1aZ77osN4AiCCZIGDEkzZWpIkgWw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <em>This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cseek,\u201d or \u201ccould\u201d and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.<\/em><br \/>\n        \n      <\/p>\n<p>\n        <strong>Repligen Contact: <\/strong><br \/>\n        <br \/>Sondra S. Newman<br \/>Global Head of Investor Relations<br \/>(781) 419-1881<br \/>investors@repligen.com\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2NiYjQwMzQtZmRlMS00NDIwLTg3MmUtMDI2NTRlYjUxNGMzLTEwMTY4MTE=\/tiny\/Repligen-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.\u00a0 Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the\u00a0Investor Relations\u00a0section of the Company\u2019s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-739768","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.\u00a0 Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the\u00a0Investor Relations\u00a0section of the Company\u2019s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of &hellip; Continue reading &quot;Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T11:35:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum\",\"datePublished\":\"2023-03-14T11:35:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/\"},\"wordCount\":364,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/\",\"name\":\"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\",\"datePublished\":\"2023-03-14T11:35:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/","og_locale":"en_US","og_type":"article","og_title":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk","og_description":"WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.\u00a0 Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the\u00a0Investor Relations\u00a0section of the Company\u2019s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of &hellip; Continue reading \"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T11:35:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum","datePublished":"2023-03-14T11:35:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/"},"wordCount":364,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/","name":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=","datePublished":"2023-03-14T11:35:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzM1MyM1NDU5Mzk3IzIwMDUyMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=739768"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=739768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=739768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=739768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}